In pharmaceutical Industry, most of the companies in Brazil have been established in São Paulo and Rio de Janeiro for a long time. In 2019, the situation was that, due to the tax advantages offered in states such as Pernambuco, Goiás and Minas Gerais, companies were leaving RJ and SP and going to these states. In 2017, Brazil was considered the sixth largest pharmaceutical market in the world. Drug sales in pharmacies reached around R $57 billion (US$17.79 billion) in the country. The pharmaceutical market in Brazil had 241 regulated and authorized laboratories for the sale of medicines. Of these, the majority (60%) have national capital. Multinational companies had approximately 52.44% of the market, with 34.75% in commercialized packaging. Brazilian laboratories represent 47.56% of the market in sales and 65.25% in cases sold. In the distribution of drug sales by state, São Paulo ranked first: São Paulo's pharmaceutical industry had a turnover of R $53.3 billion, 76.8% of total sales throughout the country. The companies that benefited the most from the sale of drugs in the country in 2015 were EMS, Hypermarcas (NeoQuímica), Sanofi (Medley), Novartis, Aché, Eurofarma, Takeda, Bayer, Pfizer and GSK.